MARKET

ONCY

ONCY

Oncolytics Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4800
-0.0003
-0.06%
After Hours: 0.4800 0 0.00% 16:00 10/11 EDT
OPEN
0.4810
PREV CLOSE
0.4803
HIGH
0.5265
LOW
0.4800
VOLUME
186.28K
TURNOVER
--
52 WEEK HIGH
3.643
52 WEEK LOW
0.3510
MARKET CAP
12.00M
P/E (TTM)
-0.6233
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONCY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ONCY News

  • The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
  • Benzinga.10/03 11:34
  • The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
  • Benzinga.10/02 11:17
  • Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
  • ACCESSWIRE.10/01 12:00
  • Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta
  • ACCESSWIRE.09/30 12:00

More

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.89%

Hot Stocks

Name
Price
%Change

About ONCY

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
More

Webull offers Oncolytics Biotech, Inc. (USA) (ONCY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.